10% Discount: Human Embryonic Stem Cell Industry (hESC) 2017 Forecasts in New Research Report at RnRMarketResearch.com

Dallas, TX (PRWEB) October 04, 2013

This report is available at a flat 10% Discount on all license types till October 31, 2013. Listed above are original prices and the discount is applicable on the same.

Stem cells are primitive cells found in all multi-cellular organisms that are characterized by self-renewal and the capacity to differentiate into any mature cell type. Categorized by stage of life, several broad categories of stem cells exist, including:

Complete report is available @ http://www.rnrmarketresearch.com/opportunities-in-human-embryonic-stem-cell-hesc-products-market-report.html.

Embryonic stem cells are stem cells derived from the inner cell mass of a blastocyst, which is a stage reached four to five days post-fertilization. They are the most pluripotent of all stem cell types and can develop into over 200 different cell types of the human body. Human embryonic stem cells (hESCs) were first derived from mouse embryos in 1981 by Martin Evans and Matthew Kaufman, and independently by Gail R. Martin. In 1995, the first successful culturing of embryonic stem cells from non-human primates occurred at the University of Wisconsin-Madison. Another breakthrough followed at the University of Wisconsin-Madison in November 1998 when a group led by Dr. James Thomson developed a technique to isolate and grow hESCs derived from human blastocysts.

As such, embryonic stem cells are still a relatively new discovery, as the first mouse embryonic stem cells (ESCs) were derived from embryos in 1981, but it was not until 1995 that the first successful culturing of embryonic stem cells from non-human primates occurred and not until November 1998 that a technique was developed to isolate and grow embryonic stem cells from human blastocysts.

Market Segments To facilitate research resulting from these advances, a large and diverse market has emerged for human embryonic stem cell products, platforms, and technologies. In total, the global sales of these items compose the hESC product marketplace. One thriving component of this marketplace is the segment of companies that sell hESC research products to scientists.

Termed research supply companies or research product vendors, large companies selling human embryonic stem cell research products include Life Technologies, BD Biosciences, Thermo Fisher Scientific, EMD Millipore, Sigma Aldrich, Lonza, R&D Systems, and STEMCELL Technologies, as well as more than 60 other suppliers that range in size from multinational corporations to small specialty companies. Together, these research supply companies represent a substantial annual percentage of hESC product sales.

As of 2013, the following product categories accounted for more than 85% of all global hESC research product sales:

In addition, pharmaceutical companies also have intense interest in human embryonic stem cell product development. Because of their plasticity and unlimited capacity for self-renewal, hESCs have been proposed for use in a wide range of pharmaceutical applications, including:

See more here:
10% Discount: Human Embryonic Stem Cell Industry (hESC) 2017 Forecasts in New Research Report at RnRMarketResearch.com